「in vitroinvivoin vitroinvivo」の検索結果
153件：86～90件目を表示
-
Presence of Products | Overseas Activities | SENJU Pharmaceutical
Asia Middle East Europe North&South Ameica Asia India Brand Name Marketing Authorisation Holder JP Brand Name GLUCOTIM－LA Centaur Pharmaceuticals PVT LTD Not marketed in JP Korea Brand Name Market...
http://www.senju.co.jp/english/global/world.html -
CEO Message | About Senju | SENJU Pharmaceutical
Since Senju was established in 1947, we have been making efforts for more than 70 years to develop excellent medicines and services focusing on the ophthalmology field through our unique ideas and R&a...
http://www.senju.co.jp/english/about/message.html -
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
f the European Societies of Toxicology 開催日：2025年9月14日～2025年9月17日 開催地：Athens, GREECE Summary of nonclinical toxicity evaluation of SJP-0132, a TRPV1 antagonist Satoko Doi1, Satomi Kikuchi2, Yoshihisa N...
http://www.senju.co.jp/english/rd/society/ -
Management Policy | About Senju | SENJU Pharmaceutical
“Being a good company” is our management policy. As a company that aims to be reliable, necessary and valuable for society, we are committed to pursuing happiness for all people associated with Senju ...
http://www.senju.co.jp/english/about/philosophy.html -
Dormolol_TE-C7_20240118
］ −1.82 ［−2.33,−1.31］ −2.78 ［−3.13,−2.43］ 配合剤群との差 ［95%信頼区間］ −0.68 ［−1.30,−0.06］ 0.28 ［−0.22,0.78］ 2 in vitro in vitro in vitro in vitro ─ 4 ─ C7 19. 有効成分に関する理化学的知見 19. 1 ドルゾラミド塩酸塩 一般名：ドルゾラミド塩酸塩 （Dorzo...
https://www.senju.co.jp/system/files/product_other_file/2024-03/dormolol_202302_C7.pdf